sameAs
P2176
P3781
Long-term Safety and Effectiveness of Levodopa-carbidopa Intestinal Gel InfusionCarbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/CarbidopaInfluence of Theta Burst Stimulation and Carbidopa-Levodopa on Motor Performance in Stroke PatientsAn Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseaseLevodopa Concentration Profile With Stalevo 75/125 mgThe Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's DiseaseImaging the Neurobiology of Behavioral and Medication Treatment for Cocaine DependenceA Study of MK0657 in Parkinson's Disease Patients (0657-006)A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-LevodopaEnhancement of Stroke Rehabilitation With LevodopaTherapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off ReversalClinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man SyndromeStudy in Advanced Parkinson's Disease Patients With Predictable Motor FluctuationsEfficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonPharmacoMRI of Parkinson DiseaseMulticentre Study in Four Parallel Groups of Parkinson's Disease (PD) PatientsA Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067Study of BIA 9-1067 to Investigate Its Effect on Levodopa PharmacokineticComparing Different Levodopa/Carbidopa/Entacapone Treatment RegimensA Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.Carbidopa-Levodopa in Dry AMD With Geographic AtrophyStudy Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's DiseaseSinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral SclerosisA Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's DiseaseObservational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's DiseasePersonality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's DiseaseWD-1603 PK Study in Healthy VolunteersL-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older AdultsHigh and Low Dose Carbidopa Treatment of Parkinson's DiseaseA Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease PatientsEfficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.Dopaminergic Modulation of Cognition and Psychomotor FunctionCarbidopa for the Treatment of Nausea and Vomiting in Familial DysautonomiaA Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease SubjectsA Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066Vision Response to Dopamine ReplacementA Study to Assess the Effect of Safinamide on Levodopa PharmacokineticsEfficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
P4844
Q61907522-5F56722B-1011-4003-A566-6A3B082266E0Q61914737-9AF7708A-3009-4838-9DAA-8BC48FB8BA47Q61920537-8B71D840-D0CA-4A77-A3E8-AF632A10F364Q61934196-4D8863CB-1791-4E2C-837A-B6EA216F5C16Q61936588-CB53CE3A-6C99-40BF-ADE7-CAB266B96D7DQ61938784-AD878E80-D32E-404E-8C80-FA247EC8FCFFQ61955618-E90E11C1-FB2B-4EE8-AE5E-1F4C7F31767CQ61956080-88CD7281-B4CE-4280-80BD-7A2481D1CD13Q61979956-6E29FA61-3884-468F-B42D-22E386904C0AQ61980695-9BBDBC4B-1820-428C-8468-239946BD9466Q62035539-F48403B7-2C3C-4E5C-BFF4-80717CEFFBBBQ62811820-8601C3CC-4411-4CAB-A214-11CFC887CDA7Q63011572-D036A978-A8E5-462B-9CA9-E9A0EA6FBB5DQ63317020-51C42A8D-CBA2-48EC-B3A7-4C641C9862A3Q63317776-6C39B94A-540B-448A-843E-EE980D1AB39DQ63317783-81CE9F45-4BAD-4921-BFED-30B3802AA657Q63317787-38D05725-315A-4ED1-BABE-3F1289BD0AB7Q63317792-52E7CF3C-7C62-4B8F-A270-406FF552B720Q63320772-C78BCEE3-D5D2-47AB-9DFE-85D70E5E6969Q63339072-A8F302B7-31B7-46E1-8E62-22C074054242Q63400004-B1630EEE-FD56-41F6-8D7A-7E1F6CC6DB70Q63400783-6B4E6223-2FEC-46ED-80FF-7CEB5035AF5EQ63403798-A23A26B6-A696-4461-99E6-E43E0EF3F3B5Q63571926-AC55C238-AFB2-42D5-8711-ABD93741BDB1Q63576973-9F72771D-B6A0-4748-8DBD-D26795B0D84FQ63578497-EC741DE7-C0C2-4F62-B7ED-32B43CA60192Q63593885-DE179085-6525-451A-9965-44BA734308D6Q63595867-8BCA0086-63BE-4117-A754-275FBE3EC548Q63595884-F1DEBFB3-8A27-46A1-AD00-8772CF94556BQ63807411-BF68C262-6A34-48E9-9C8E-6B9DCBC33615Q63807895-F009C734-B36F-42C3-B322-C26E41986D1DQ63816421-324E57F0-9AE8-48A2-AE29-8CBFDBBF81EDQ63816709-55E61BD0-7A7A-41FC-A437-D4475E143048Q63818124-4755B290-F113-42AC-A15E-241B3CE3103CQ63819076-D3C44A94-5A29-4EFE-88A8-FE46B20B720EQ63831358-BC57E8BB-4376-4560-9ECA-2068D85DBD72Q63835953-435CE04C-CA63-4F0C-B32D-6E35DADFAF45Q63838407-0F50044A-1E14-48E8-8578-A03870DC77D6Q63838983-A943F24C-A7F1-4FFE-8EC2-84AFF2A6ED07Q63844806-C41CC121-985A-47CC-9F3A-B0F0983A572C
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
(S)-(−)-Carbidopa-Monohydrat
@de
(S)-(−)-carbidopa monohydrate
@en
Carbidopa
@es
Carbidopa
@it
Carbidopa
@nl
Carbidopa
@pt
Karbidopa
@fi
Karbidopa
@pl
Karbidopa
@sh
Karbidopa
@sr
type
label
(S)-(−)-Carbidopa-Monohydrat
@de
(S)-(−)-carbidopa monohydrate
@en
Carbidopa
@es
Carbidopa
@it
Carbidopa
@nl
Carbidopa
@pt
Karbidopa
@fi
Karbidopa
@pl
Karbidopa
@sh
Karbidopa
@sr
altLabel
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
@en
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
@en
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
@cy
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
@en
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
@cy
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
@en
(S)-(-)-Carbidopa hydrate
@cy
(S)-(-)-Carbidopa hydrate
@en
(S)-(−)-carbidopa hydrate
@cy
(S)-(−)-carbidopa hydrate
@en
prefLabel
(S)-(−)-Carbidopa-Monohydrat
@de
(S)-(−)-carbidopa monohydrate
@en
Carbidopa
@es
Carbidopa
@it
Carbidopa
@nl
Carbidopa
@pt
Karbidopa
@fi
Karbidopa
@pl
Karbidopa
@sh
Karbidopa
@sr
P2868
P672
P486
P592
P646
P661
P662
P665
P6694
P683
P1579
P1987
2928.00.20
P2017
C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O